 Telegraph.co.uk | NICE draft rejects everolimus for advanced breast cancer OnMedica NICE's decision today not to recommend everolimus (Afinitor) has met with anger from women with advanced breast cancer who have limited treatment options available. But Breast Cancer Campaign has urged doctors to try to provide it through the Cancer ... Breakthrough breast cancer drug 'too expensive' Breast cancer treatment 'not value for money' NICE issues negative draft decision for Novartis' Afinitor |
